Which has the lower trailing P/E, CORT or HALO?

HALO has the lower trailing P/E: CORT trades at 289.12 and HALO at 32.75. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CORT or HALO?

Over the past five years, HALO grew revenue faster — CORT at a 19.35% CAGR versus HALO at 32.18%.

Is CORT or HALO more profitable?

HALO runs the higher net margin — CORT at 6.61% versus HALO at 24.86%.

How have CORT and HALO total returns compared?

Over the past 10 years, CORT delivered 33.70% and HALO delivered 24.30% annualized total return. Past performance doesn't predict future results.

Corcept Therapeutics Incorporated (CORT) vs Halozyme Therapeutics, Inc. (HALO)

A side-by-side comparison of Corcept Therapeutics Incorporated and Halozyme Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CORT

Corcept Therapeutics Incorporated

$13.13B

$121.43HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

HALO

Halozyme Therapeutics, Inc.

$13.01B

$109.70HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

Total return — CORT vs HALO

growth of $100 · dividends reinvested · last 10y

CORT +1837.0% (+34.5%/yr)HALO +779.9% (+24.3%/yr)CORT compounded faster over this window

CORT HALO

CORT vs HALO: by the numbers

•CORT is the larger company ($13.13B vs $13.01B market cap).
•HALO trades at the lower trailing earnings multiple (32.75 vs 289.12 P/E), one valuation lens rather than an overall verdict.
•HALO converts more revenue to profit (24.86% vs 6.61% net margin).
•HALO grew revenue faster over the past five years (32.18% vs 19.35% CAGR).

Metrics side by side

Valuation

Metric	CORT	HALO
P/E ratio	289.12	32.75
Forward P/E	N/A	13.04
PEG ratio	N/A	1.43
P/S ratio	15.80	7.82
P/B ratio	18.60	90.65
EV / EBITDA	1475.89	14.22
FCF yield	0.81%	6.20%

Profitability

Metric	CORT	HALO
Gross margin	98.30%	78.18%
Operating margin	0.77%	56.77%
Net margin	6.61%	24.86%
ROE	7.78%	288.13%
ROIC	0.87%	27.42%

Growth (annualized)

Metric	CORT	HALO
Revenue CAGR (5Y)	19.35%	32.18%
EPS CAGR (5Y)	0.64%	22.68%
FCF CAGR (5Y)	-4.40%	40.08%
Total return CAGR (5Y)	43.90%	22.18%

Frequently asked

Which has the lower trailing P/E, CORT or HALO?: HALO has the lower trailing P/E: CORT trades at 289.12 and HALO at 32.75. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CORT or HALO?: Over the past five years, HALO grew revenue faster — CORT at a 19.35% CAGR versus HALO at 32.18%.
Is CORT or HALO more profitable?: HALO runs the higher net margin — CORT at 6.61% versus HALO at 24.86%.
How have CORT and HALO total returns compared?: Over the past 10 years, CORT delivered 33.70% and HALO delivered 24.30% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysis Full HALO analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio Halozyme Therapeutics P/E ratio Corcept Therapeutics ROE Halozyme Therapeutics ROE Corcept Therapeutics operating margin Halozyme Therapeutics operating margin Corcept Therapeutics revenue growth Halozyme Therapeutics revenue growth Corcept Therapeutics free cash flow Halozyme Therapeutics free cash flow

Corcept Therapeutics & Halozyme Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.